NCT03440567View on ClinicalTrials.gov

Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

April 2, 2018

Primary Completion Date

June 26, 2024

Study Completion Date

June 26, 2024

Conditions
Recurrent Diffuse Large B-Cell LymphomaRecurrent Mantle Cell LymphomaRefractory Diffuse Large B-Cell LymphomaRefractory Mantle Cell LymphomaTransformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
PROCEDURE

Autologous Hematopoietic Stem Cell Transplantation

Undergo autologous hematopoietic stem cell transplantation

DRUG

Avelumab

Given IV

DRUG

Carboplatin

Given IV

DRUG

Etoposide Phosphate

Given IV

DRUG

Ibrutinib

Given PO

DRUG

Ifosfamide

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Rituximab

Given IV

BIOLOGICAL

Utomilumab

Given IV

Trial Locations (1)

91010

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER

NCT03440567 - Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma | Biotech Hunter | Biotech Hunter